LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: DAMPening Tumor Immune Escape: The Role of Endoplasmic Reticulum Chaperones in Immunogenic Chemotherapy.

    Cifric, Selma / Turi, Marcello / Folino, Pietro / Clericuzio, Cole / Barello, Francesca / Maciel, Tallya / Anderson, Kenneth C / Gulla, Annamaria

    Antioxidants & redox signaling

    2024  

    Abstract: Significance: ...

    Abstract Significance:
    Language English
    Publishing date 2024-03-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1483836-9
    ISSN 1557-7716 ; 1523-0864
    ISSN (online) 1557-7716
    ISSN 1523-0864
    DOI 10.1089/ars.2024.0558
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.

    Gulla, Annamaria / Morelli, Eugenio / Johnstone, Megan / Turi, Marcello / Samur, Mehmet K / Botta, Cirino / Cifric, Selma / Folino, Pietro / Vinaixa, Delaney / Barello, Francesca / Clericuzio, Cole / Favasuli, Vanessa Katia / Maisano, Domenico / Talluri, Srikanth / Prabhala, Rao H / Bianchi, Giada / Fulciniti, Mariateresa / Wen, Kenneth / Kurata, Keiji /
    Liu, Jiye / Penailillo, Johany / Bragoni, Alberto / Sapino, Anna / Richardson, Paul G / Chauhan, Dharminder / Carrasco, Ruben D / Hideshima, Teru / Munshi, Nikhil C / Anderson, Kenneth C

    Blood

    2024  

    Abstract: Immunogenic cell death (ICD) is a form of cell death by which cancer treatments can induce a clinically relevant anti-tumor immune response in a broad range of cancers. In multiple myeloma (MM), the proteasome inhibitor bortezomib is an ICD inducer and ... ...

    Abstract Immunogenic cell death (ICD) is a form of cell death by which cancer treatments can induce a clinically relevant anti-tumor immune response in a broad range of cancers. In multiple myeloma (MM), the proteasome inhibitor bortezomib is an ICD inducer and creates durable therapeutic responses in patients. However, eventual relapse and resistance to bortezomib appear inevitable. Here, by integrating patient transcriptomic data with an analysis of calreticulin (CRT) protein interactors, we found that GABARAP is a key player whose loss prevented tumor cell death from being perceived as immunogenic after bortezomib treatment. GABARAP is located on chromosome 17p, which is commonly deleted in high-risk MM patients. GABARAP deletion impaired the exposure of the eat-me signal CRT on the surface of dying MM cells in vitro and in vivo, thus reducing tumor cell phagocytosis by dendritic cells and the subsequent anti-tumor T cell response. Low GABARAP was independently associated with shorter MM patient survival and reduced tumor immune infiltration. Mechanistically, we found that GABARAP deletion blocked ICD signaling by decreasing autophagy and altering Golgi apparatus morphology, with consequent defects in the downstream vesicular transport of CRT. Conversely, upregulating autophagy using rapamycin restored Golgi morphology, CRT exposure and ICD signaling in GABARAPKO cells undergoing bortezomib treatment. Therefore, coupling an ICD inducer, like bortezomib, with an autophagy inducer, like rapamycin, may improve patient outcomes in MM, where low GABARAP in the form of del(17p) is common and leads to worse outcomes.
    Language English
    Publishing date 2024-03-29
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2023022777
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top